-
Garcia keeps WBC welterweight title by stopping Benn
-
Hong Kong homes flattened for US$28 bn high-tech hub
-
Lights out in Laos as electricity exports surge
-
'Be careful what you wish for': 'Obsession' director and star reflect on success
-
'This is the test': All eyes on US Fed to tackle high inflation
-
Messi scores but Miami held by Nashville
-
Scars of Marawi siege linger as Philippines poll nears
-
US Open champ Rybakina on top of world after injury scare
-
Trump turns to golf, family business on Irish visit's second day
-
Rybakina reigns serene as new world number one
-
Best Online Gold Dealers in USA 2026 Rankings Released By Experts
-
Defiant Sabalenka motivated by US Open defeat
-
South Africa defeat New Zealand 43-28 to complete 3-1 series victory
-
Houthis say hit Saudi base after renewed fighting with Yemeni govt forces
-
Rybakina triumphs in US Open, denies Sabalenka three-peat
-
Fifth Circuit upholds dismissal of Jackson residents' constitutional water claims
-
Mini 1998 GT pairs 161-hp engine with John Cooper Works chassis hardware
-
Japanese floating parking platform is designed to lift cars above floodwater
-
GTA VI draws political criticism online as preorder estimates exceed five million
-
Anthropic details Claude misuse as US targets major illicit online marketplace
-
Steven Strogatz weighs AI mathematics advances and their consequences for researchers
-
KFF journalists discuss opioid funds, suicide prevention and gaps in care
-
Winston County trash-debt prosecutions face challenge from civil-rights lawyers
-
Roadless Rule repeal proposal raises concerns over Midwest forests and fire risk
-
Marmot research gains over $140,000 from meme-coin fees alongside wildlife contest
-
Utah hosts Arkansas as both programs begin seasons under new coaches
-
Queens residents seek renewed enforcement along Roosevelt Avenue
-
Christa Pike seeks clemency before September 30 execution in Tennessee
-
United States beats Spain 76-66 to set up World Cup final against France
-
Louisiana's developing roster faces USC as Trojans enter as heavy favorites
-
Cristian Mungiu's Fjord examines a family's conflict with Norwegian child authorities
-
Akron fan's honorary play-calling stint ends with opening-drive fumble
-
Gilbert Arenas questions Jonathan Kuminga's decision to join Minnesota
-
Maryland groups seek statewide data center pause after local moratoriums spread
-
Arteta blasts 'unacceptable' Sunderland penalty despite Arsenal win
-
Attissogbe double inspires Pau to Top 14 summit
-
Mbappe at the double as Real Madrid sink Rayo
-
Guimaraes strike lights up Arsenal win over Sunderland
-
Arsenal extend perfect Premier League start as Chelsea, Liverpool held
-
Israeli-made Gaza documentary wins Venice special jury prize
-
US survive Spain scare to book World Cup final clash with France
-
De Zerbi apologises to fans after Spurs' stalemate extends goal drought
-
Celine Dion makes long-awaited return to stage in Paris
-
Lowry takes four-shot lead as Trump jets in for Irish Open
-
Werro crowned Ultimate queen, US sweep 100m races
-
Harrison, Skupski win US Open men's doubles title
-
Venezuelans outside Caracas say capital not sharing blackout burden
-
Verstappen fears overtaking will be 'tough' at Spanish GP
-
Danish WWII drama wins top prize at Venice festival
-
Argentina revives plan for South Atlantic naval base amid Falklands tensions
US Supreme Court to weigh in on abortion pill ban
The US Supreme Court will step into the divisive and emotional battle over the abortion drug mifepristone Wednesday, when it is expected to rule on tough new court-ordered restrictions on the widely used pill.
It sets up the conservative-leaning bench for its most significant intervention on reproductive rights since a seismic ruling 10 months ago that stripped women in America of the constitutional right to a termination.
Since then, anti-abortion groups have refocused their efforts on banning mifepristone, which was approved by the Food and Drug Administration (FDA) back in 2000 and currently accounts for more than half of all abortions in the United States.
Those efforts bore fruit earlier this month when a federal judge said the FDA approval was flawed and the drug should be withdrawn.
An appeals court blocked any ban on the pill, but imposed tough restrictions on access, after which the baton was handed to the Supreme Court which has until midnight Wednesday to step in.
The multi-level rulings and temporary stays have created a climate of legal confusion and uncertainty that has only heightened concerns and anxieties among those who oppose what they view as an all-out assault on women's reproductive rights.
Since the Supreme Court overturned the landmark Roe v. Wade ruling that had enshrined the constitutional right to abortion for half a century, around two dozen states have either banned or severely restricted access to abortion.
- Regulatory chaos -
The fresh battle over mifepristone has descended into a "judicial ping pong game," according to Carrie Flaxman, a senior director of public policy litigation with Planned Parenthood, a leading abortion provider and advocacy group.
The back and forth is impacting access to "safe and effective medication" and is "causing chaos and confusion," Flaxman said.
Ushma Upadhyay, a public health scientist at the University of California San Francisco, said it was "untenable" for providers and patients to be "living day to day under these ever-changing rules and interpretations."
Opposition to the legal attack on the abortion pill is being spearheaded by the Department of Justice, which argued that the initial judge's ruling was based on a "deeply misguided assessment" of the pill's safety.
The department urged the Supreme Court to preserve full access to the medication pending a full hearing at the appellate level, or take the case on itself on an "expedited" basis.
Mifepristone is one component of a two-drug regimen that can be used through the first 10 weeks of pregnancy. It has a long safety record, and the FDA estimates 5.6 million Americans have used it to terminate pregnancies since it was approved.
The Supreme Court, which has a 6-3 conservative majority, could decide to reinstate the restrictions put in place at the appellate level, the total ban, or some other configuration.
In a filing to the court on Tuesday, the anti-abortion coalition that first brought the case against the FDA repeated their controversial claims that the drug was unsafe.
The coalition said the FDA and the distributor of mifepristone had "brazenly flouted the law and applicable regulations ... and continually placed politics above women's health."
Polls repeatedly show a clear majority of Americans support continued access to safe abortion, even as conservative groups push to limit the procedure -- or ban it outright.
Pregnancies are successfully terminated in more than 95 percent of cases where mifepristone is used, according to studies.
Serious complications -- excessive bleeding, fever, infection or allergic reaction -- which require a medical consultation, are rare.
E.Rodriguez--AT